Evidence map›Paper›PMID 40830172›Full record

Trial reportScientific reports2025

Reduced serum iron levels predict poor prognosis in pulmonary mucormycosis patients: a prospective, case‒control study.

Qiongzhen Luo, Xinwei He, Jiao Xu, Li Li, Lina Zhao, Xiangdong Mu

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06495905 (Evaluation of the Effectiveness and Safety of Transbronchoscopic Infusion of Amphotericin B + Inhalation of Amphotericin B + Transbronchoscopic Debridement + Systematic Antifungal Multimodal Treatment of Pulmonary Mucormycosis), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06495905 naunknown statusnot on this map

Evaluation of the Effectiveness and Safety of Transbronchoscopic Infusion of Amphotericin B + Inhalation of Amphotericin B + Transbronchoscopic Debridement + Systematic Antifungal Multimodal Treatment of Pulmonary Mucormycosis

TypeinterventionalSponsorBeijing Tsinghua Chang Gung HospitalRan2024 to 2025Enrolled30ConditionsPulmonary MucormycosisArmstransbronchoscopic interventional debridement
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiongzhen Luo *Department of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Xinwei He *Department of Internal Medicine, Xicheng District Zhanlanlu Hospital, Beijing, People's Republic of China.
Jiao XuDepartment of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Li LiDepartment of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Lina ZhaoDepartment of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
Xiangdong MuDepartment of Respiratory and Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China. mxda02600@btch.edu.cn.

Funding

Beijing Hospitals Authority Clinical Medicine Development of special funding support ZLRK202323
6 · The paper itself

Abstract

Pulmonary mucormycosis (PM) and invasive pulmonary aspergillosis (IPA) are both invasive pulmonary fungal infections with similar clinical manifestations. Few studies have focused on the expression of serum iron in patients with PM and IPA. A prospective, case‒control study was conducted between January 2023 and December 2024. Patients diagnosed with PM or IPA were assigned to the PM group or the IPA group, respectively. Clinical data were recorded for all enrolled patients. Serum iron, serum ferritin, unsaturated iron-binding capacity (UIBC), total iron-binding capacity (TIBC), and percentage transferrin saturation levels were determined via an automatic biochemical detector. A total of 58 patients with PM and 49 patients with IPA were enrolled. Nine patients in the PM group and one patient in the IPA group died during hospitalization. The serum iron, UIBC, and TIBC levels in the PM group were significantly lower than those in the IPA group (all p < 0.05). The serum ferritin level was significantly greater in the PM group than in the IPA group (p = 0.021). Binary logistic regression analysis revealed that only the TIBC level was an independent risk factor for PM [OR (95% CI) = 0.892 (0.839-0.947), p < 0.001]. Cox proportional hazards regression analysis revealed that the serum iron concentration [HR (95% CI) = 0.872 (0.784-0.969); p = 0.011] was an independent predictor of mortality risk in PM patients. Lower TIBC levels at admission were associated with a greater risk of PM, and reduced serum iron levels predict poor prognosis in patients with PM. Using IPA patients as controls, we preliminarily revealed aberrant iron metabolism in PM patients.Trial registration: ClinicalTrials.gov ID NCT06495905, Date of registration July 11, 2024 (retrospectively registered).

Indexed as

Invasive Pulmonary AspergillosisIronLung Diseases, FungalMucormycosisAdultAgedBiomarkersCase-Control StudiesFemaleFerritinsHumansMaleMiddle AgedPrognosisProspective StudiesRisk FactorsBiomarkersFerritinsIronInvasive pulmonary aspergillosisPrognosisPulmonary mucormycosisSerum ironTotal iron-binding capacity

Identifiers

PMID40830172
PMCPMC12365034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.